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1. INTRODUCTION {#cam42276-sec-0005}
===============

The number of people living after a cancer diagnosis showed an approximately 3% annual increase in the USA, Italy, and UK.[1](#cam42276-bib-0001){ref-type="ref"}, [2](#cam42276-bib-0002){ref-type="ref"}, [3](#cam42276-bib-0003){ref-type="ref"} This trend is mainly powered by the increasing number of new diagnoses because of population aging, and improved survival associated with advanced treatments and early diagnosis. Patients living after a cancer diagnosis (ie, prevalent cases) include those currently in treatment; those who have become cancer‐free but still have a measurable excess risk of recurrence or death; and patients who can be considered "cured", as they have reached the same death rates of the general population.[4](#cam42276-bib-0004){ref-type="ref"} Notably, nearly four million people are expected to be living after a cancer diagnosis in Italy in 2020 (ie, one out of 17 Italians).[1](#cam42276-bib-0001){ref-type="ref"} In addition, patients who were diagnosed since ≥15 years represented one fifth (20%) of all Italian prevalent cases in 2010, and this proportion is projected to reach approximately 40% in 2020.[1](#cam42276-bib-0001){ref-type="ref"} Notwithstanding, relatively few studies have attempted to categorize prevalent cancer patients according to the probability of being cured.[4](#cam42276-bib-0004){ref-type="ref"}, [5](#cam42276-bib-0005){ref-type="ref"}, [6](#cam42276-bib-0006){ref-type="ref"}, [7](#cam42276-bib-0007){ref-type="ref"}, [8](#cam42276-bib-0008){ref-type="ref"}, [9](#cam42276-bib-0009){ref-type="ref"}, [10](#cam42276-bib-0010){ref-type="ref"}

The aim of the present study was to provide reliable and updated estimates for Italian patients of three indicators that are still lacking in current cancer statistics,[11](#cam42276-bib-0011){ref-type="ref"}, [12](#cam42276-bib-0012){ref-type="ref"} that is, long‐term survival and cure, according to cancer type, sex, and age. These indicators are meant to provide helpful information to public health operators in treatment evaluation, to oncologists in planning patients' follow‐up,[13](#cam42276-bib-0013){ref-type="ref"}, [14](#cam42276-bib-0014){ref-type="ref"}, [15](#cam42276-bib-0015){ref-type="ref"} to policy makers for an evidence‐based planning of financial resources allocation, and, most of all, they could be of special interest to the increasing number of people living after a cancer diagnosis.[1](#cam42276-bib-0001){ref-type="ref"}, [16](#cam42276-bib-0016){ref-type="ref"}

2. MATERIALS AND METHODS {#cam42276-sec-0006}
========================

This study used data collected by 8 population‐based Italian cancer registries,[11](#cam42276-bib-0011){ref-type="ref"} which agreed to participate in the study, with at least 18 years of cancer registration as of 31 December 2011 (ie, Ferrara, Genova, Modena, Parma, Ragusa, Sassari, Varese, and Veneto, representing 10% of the entire Italian population in 2010).[11](#cam42276-bib-0011){ref-type="ref"}, [17](#cam42276-bib-0017){ref-type="ref"}

The study included all malignant tumors (ICD‐10: C00‐C43, C45‐C96), and those with benign/uncertain behavior or in situ bladder cancers. Nonmelanoma skin cancers (ICD‐10 C44) were excluded. ICD‐O‐3 classification was used to identify subtypes (Table [1](#cam42276-tbl-0001){ref-type="table"}).

###### 

Cancer cases (N) and crude incidence rates (CIR), Italian cancer registries areas 1985‐2011

  Cancer type               ICD10/ICDO3                    BOTH SEXES   MEN       WOMEN                                                                                     
  ------------------------- ------------------------------ ------------ --------- ------- -------- -------- -------- --------- --------- ------- -------- -------- -------- --------
  Oral cavity and pharynx   C01‐14                         12,536       9,663     19.7    760      2,139    3,599    3,165     2,873     5.7     374      562      889      1,048
  Esophagus                 C15                            4,678        3,922     8.0     131      661      1,425    1,705     756       1.5     27       104      243      382
  Stomach                   C16                            19,407       12,701    25.9    551      1,438    3,895    6,817     6,706     13.2    437      843      1,795    3,631
  Colon                     C18                            41,089       23,228    47.3    860      2,565    7,403    12,400    17,861    35.2    838      2,489    5,530    9,004
  Rectum                    C19‐20                         17,782       10,995    22.4    418      1,417    3,695    5,465     6,787     13.4    328      1,068    2,160    3,231
  Liver                     C22                            16,140       12,195    24.8    316      1,287    3,967    6,625     3,945     7.8     107      286      948      2,604
  Gallbladder               C23‐24                         5,119        2,286     4.7     47       233      679      1,327     2,833     5.6     54       254      810      1,715
  Pancreas                  C25                            12,844       7,378     15.0    237      918      2,400    3,823     5,466     10.8    168      480      1,539    3,279
  Larynx                    C32                            9,566        8,831     18.0    247      1,419    3,504    3,661     735       1.4     32       124      276      303
  Lung                      C33‐34                         62,608       50,802    103.5   961      5,044    16,949   27,848    11,806    23.2    526      1,635    3,569    6,076
  Skin melanoma             C43                            13,544       6,753     13.8    1,746    1,435    1,769    1,803     6,791     13.4    2,507    1,408    1,429    1,447
  Mesothelioma              C45                            2,324        1,759     3.6     48       200      582      929       565       1.1     23       79       168      295
  Connective tissue         C47,49                         2,898        1,596     3.3     382      296      423      495       1,302     2.6     337      228      323      414
  Breast                    C50                            80,224       616       1.3                                          79,608    156.7   11,823   20,449   23,348   23,988
  Cervix uteri              C53                            5,125                                                               5,125     10.1    1,600    1,257    1,153    1,115
  Corpus uteri              C54                            12,735                                                              12,735    25.1    652      2,410    4,777    4,896
  Ovary                     C56                            8,475                                                               8,475     16.7    1,131    1,863    2,556    2,925
  Prostate                  C61                            43,623       43,623    88.8    54       1,766    12,868   28,935                                                  
  Testicular                C62                            3,421        3,421     7.0     2,772    408      162      79                                                      
  Kidney                    C64‐66,68                      17,552       12,125    24.7    826      1,826    4,109    5,364     5,427     10.7    435      783      1,652    2,557
  Bladder                   C67,D090,D303,D414             32,209       26,649    54.3    1,017    2,820    8,387    14,425    5,560     10.9    341      610      1,632    2,977
  Brain                     C70‐72                         8,706        4,942     10.1    1,021    844      1,439    1,638     3,764     7.4     692      596      1,034    1,442
  Thyroid                   C73                            13,089       3,249     6.6     1,082    703      779      685       9,840     19.4    3,545    2,364    2,227    1,704
  Hodgkin lymphoma          C81                            4,028        2,185     4.5     1,338    293      299      255       1,843     3.6     1,253    182      212      196
  Non‐Hodgkin lymphoma      C82‐85,96                      19,214       10,650    21.7    2,078    1,715    2,895    3,962     8,564     16.9    1,356    1,289    2,331    3,588
  SLL/CLL                   M9670,9823                     4,932        3,058     6.2     123      347      1,018    1,570     1,874     3.7     64       247      571      992
  NHL, diffuse large B      M9678‐9684                     4,982        2,811     5.7     659      457      686      1,009     2,171     4.3     423      301      490      957
  NHL, follicular           M9675,9690‐9698                3,116        1,493     3.0     298      313      432      450       1,623     3.2     248      282      527      566
  Acute myeloid leukaemia   M9840,9861,9866‐9867,          3,377        1,804     3.7     332      248      457      767       1,573     3.1     321      222      403      627
                            9870‐9874,9891‐9931                                                                                                                              
  Multiple myeloma          M9731‐9734                     6,669        3,536     7.2     164      468      1,125    1,779     3,133     6.2     132      396      929      1,676
  All types                 C00‐43,45‐96, D090,D303,D414   508,617      281,687   573.7   19,400   32,524   87,862   141,901   226,930   446.8   30,425   43,823   65,414   87,268

Cancer Registries with ≥18 years of observation, age 15‐74 years; Cancer type or subtype with \>2000 cases in the period and areas covered by CRs.

John Wiley & Sons, Ltd

The observed relative survival (RS) was calculated for adult cases (aged 15‐74 years) diagnosed in 1985‐2011 and followed‐up until 2013, using the cohort method and the Ederer II approach.[4](#cam42276-bib-0004){ref-type="ref"}, [12](#cam42276-bib-0012){ref-type="ref"}

Indicators of long‐term survival and cancer cure were obtained by applying, for each combination of cancer type and sex, mixture cure models to RS data, stratified by age groups (15‐44, 45‐54, 55‐64, 65‐74 years), and three‐year diagnostic periods (ie, 1985‐1987, 1988‐1990\..., 2009‐2011).[18](#cam42276-bib-0018){ref-type="ref"}, [19](#cam42276-bib-0019){ref-type="ref"} Only cancer types (first two ICD10 digits, or ICDO3 groups for hemopoietic neoplasms) with at least 2 000 adult cases recorded in the Italian registries in 1985‐2011 were considered (Table [1](#cam42276-tbl-0001){ref-type="table"}).

The three indicators of long‐term survival and cancer cure for Italian patients were defined as follows: (a) median life expectancy of fatal tumors (LEFT), reached when 50% of patients with a fatal tumor had died[18](#cam42276-bib-0018){ref-type="ref"}; (b) the proportion of cancer patients expected to reach the same death rates of the general population of the same sex and age (cure fraction, CF)[4](#cam42276-bib-0004){ref-type="ref"}, [18](#cam42276-bib-0018){ref-type="ref"}, [20](#cam42276-bib-0020){ref-type="ref"}; and (c) the number of years after cancer diagnosis necessary to eliminate, or at least to make negligible, the excess mortality due to cancer (time to cure, TTC).[4](#cam42276-bib-0004){ref-type="ref"}, [6](#cam42276-bib-0006){ref-type="ref"}

From a statistical and epidemiological point of view, CF is reached when the cancer specific excess mortality approaches zero and patients will die of causes other than that neoplasm.[21](#cam42276-bib-0021){ref-type="ref"} Given the conditional relative survival (CRS) as the survival experience of the cohort alive *n* years after the diagnosis of a specific cancer, the TTC was measured as the number of years necessary for model‐based 5‐year CRS to reach 90% or 95%, two clinically or epidemiologically relevant thresholds of fading cancer excess mortality.[4](#cam42276-bib-0004){ref-type="ref"}, [6](#cam42276-bib-0006){ref-type="ref"}

For most cancer types, a Weibull distribution was used to model the excess mortality function for fatal cases (ie, those who will never reach the same death rates of the general population). For breast cancer in women, bladder and thyroid cancers, and Hodgkin lymphoma a better fit was obtained by using an exponential distribution. All models were stratified by age, assuming linearity in the period of diagnosis effects.[18](#cam42276-bib-0018){ref-type="ref"} Changes of LEFT and CF over time were calculated accordingly for two periods of diagnosis (1990 and 2000).

The goodness of fit of model‐based RS was evaluated using the likelihood ratio test and cure models converged for every cancer type and sex. In addition, a comparison of observed and model‐based RS and 5‐year CRS was conducted[22](#cam42276-bib-0022){ref-type="ref"} until 25 years after diagnosis for all cancer types, sex, age groups, and period of diagnosis (Appendices [S1](#cam42276-sup-0001){ref-type="supplementary-material"} and [S2](#cam42276-sup-0001){ref-type="supplementary-material"}). The model fitting to observed RS was good with few exceptions for cancer types with a very poor long‐term survival. For these cancers, inconsistencies between the observed and model‐based CRS emerged. Therefore, TTC were presented only for cancer types with a CF \>20% in men or women.

3. RESULTS {#cam42276-sec-0007}
==========

More than half a million Italian cancer patients aged 15‐74 years in 1985‐2011 (281 687 men and 226 930 women) contributed to the study (Table [1](#cam42276-tbl-0001){ref-type="table"}), 79 608 women with breast cancer, 62 608 cases with lung, 43 623 with prostate, and 41 089 with colon cancers.

In 1990 and in both sexes, the median LEFT was less than half a year for patients with liver, gallbladder, pancreas, lung, brain cancers, and with acute myeloid leukemias (Table [2](#cam42276-tbl-0002){ref-type="table"}). Conversely, a median LEFT longer than five years was estimated ‐in 1990‐ for cancers of the larynx (\>10 years), breast (8.1), prostate (5.2), and follicular lymphomas (6.6). They were 5.8 years for testicular cancer, and 6.3 years in men and 6.9 years in women with Hodgkin lymphoma diagnosed below age 45 years (ie, the vast majority of cases).

###### 

Median life expectancy of fatal tumors by cancer type, sex, and period. Italy

  Year of diagnosis                                         MEN    WOMEN                                        
  --------------------------------------------------------- ------ ------- ------- ----- ------ ------- ------- -----
  Oral cavity and pharynx                                   1.9    2.2     0.36    19%   3.8    4.2     0.42    11%
  Esophagus                                                 0.6    0.7     0.15    26%   0.7    0.8     0.13    19%
  Stomach                                                   0.6    0.7     0.11    17%   0.7    0.8     0.06    9%
  Colon                                                     1.4    1.6     0.14    10%   1.5    1.6     0.12    8%
  Rectum                                                    2.0    2.2     0.21    10%   1.9    2.1     0.19    10%
  Liver                                                     0.4    0.7     0.32    80%   0.5    0.8     0.34    69%
  Gallbladder                                               0.4    0.6     0.12    27%   0.4    0.4     0.10    27%
  Pancreas                                                  0.3    0.4     0.09    29%   0.4    0.5     0.11    29%
  Larynx                                                    10.9   10.8    −0.10   −1%   10.1   13.6    3.50    35%
  Lung                                                      0.5    0.6     0.09    16%   0.5    0.7     0.16    29%
  Skin melanoma                                             2.5    2.8     0.33    13%   4.3    4.6     0.27    6%
  Mesothelioma                                              0.9    1.0     0.12    13%   1.0    1.1     0.09    10%
  Connective tissue                                         2.2    2.4     0.13    6%    2.0    2.1     0.15    8%
  Breast[b](#cam42276-note-0007){ref-type="fn"}                                          8.1    9.4     1.38    17%
  Cervix uteri                                                                           2.4    2.5     0.09    4%
  Corpus uteri                                                                           3.9    4.0     0.10    3%
  Ovary                                                                                  1.8    2.0     0.23    13%
  Prostate                                                  5.2    7.4     2.21    42%                           
  Testicular[a](#cam42276-note-0006){ref-type="fn"}         5.8    6.1     0.22    4%                            
  Kidney                                                    8.5    \>15    --      --    3.2    4.2     0.96    30%
  Bladder[b](#cam42276-note-0007){ref-type="fn"}            4.3    4.7     0.44    10%   3.3    3.5     0.21    6%
  Brain                                                     0.5    0.6     0.11    24%   0.4    0.6     0.14    31%
  Thyroid[a](#cam42276-note-0006){ref-type="fn"}            3.6    3.7     0.08    2%    4.6    4.6     0.02    0%
  Hodgkin lymphoma[a](#cam42276-note-0006){ref-type="fn"}   6.3    6.6     0.30    5%    6.9    7.5     0.61    9%
  Non‐Hodgkin lymphoma                                      3.1    5.0     1.94    63%   5.4    9.7     4.35    81%
  SLL/CLL[c](#cam42276-note-0008){ref-type="fn"}            3.6    3.6     0.04    1%    5.1    4.9     −0.21   −4%
  NHL, diffuse large B                                      0.9    1.2     0.27    29%   1.8    2.1     0.38    22%
  NHL, follicular                                           6.6    11.8    5.25    80%   6.6    12.90   6.28    95%
  Acute myeloid leukaemia                                   0.3    0.5     0.18    40%   0.3    0.5     1.01    28%
  Multiple myeloma                                          3.0    4.2     1.19    66%   3.7    4.7     0.19    57%
  All types                                                 1.0    1.4     0.41    40%   2.3    2.7     0.46    20%

Calculated as the median (50th percentile) relative survival, estimated through the best fitting model‐based distributions. Patients aged 15‐74 years, except when specified.

Patients aged 15‐44 years.

Patients aged 65‐74 years.

Patients aged 55‐74 years.

John Wiley & Sons, Ltd

Between 1990 and 2000, the median LEFT increased by more than one year for patients with breast (from 8.1 to 9.4 years) or prostate cancer (from 5.2 to 7.4 years), and ‐in both sexes‐ non‐Hodgkin lymphoma (NHL), in particular follicular NHL. Conversely, a limited (ie, \<2 months) increase was estimated for stomach, colon, gallbladder, pancreas, lung, cervix and corpus uteri, brain, thyroid cancers and small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL). For most cancer types, the median LEFT slightly decreased with age (Appendix [S3](#cam42276-sup-0001){ref-type="supplementary-material"}).

For cancer cases diagnosed in 2000, the CF was 39% for the combination of all cancer types (ie, weighted by the number of cases by type and age) in men (Figure [1](#cam42276-fig-0001){ref-type="fig"}). CF was \>50% for patients with testicular cancers (94%), thyroid (83%), prostate (75%), skin melanoma (75%), Hodgkin lymphoma (70%), bladder (59%) or colon cancers (54%). In women, the CF for all cancers was 52%, the highest CF was estimated for thyroid cancer (95%), skin melanoma (83%), Hodgkin lymphoma (77%), corpus uteri (70%), bladder (69%), and breast cancer (67%). Conversely, for cases diagnosed until 2000, a CF \<10% was estimated in both sexes for cancers of the liver and pancreas, mesothelioma, and SLL/CLL. The CF increased approximately 10 percentage points between 1990 and 2000 for most common cancer types (ie, colon and rectum, breast or bladder cancer), and across most age groups (Appendix [S4](#cam42276-sup-0001){ref-type="supplementary-material"}). Notably, a nearly doubled CF emerged in Italy for prostate cancers between 1990 and 2000, while only a limited (\<5%) increase was observed for the other most fatal cancer types. A marked CF decrease emerged with age (Appendix [S4](#cam42276-sup-0001){ref-type="supplementary-material"}).

![Estimated cure fraction (%)^a^ by sex, cancer type, and year of diagnosis in Italy. ^a^Calculated as weighted means of corresponding cure fractions for the four age groups (Appendix [S4](#cam42276-sup-0001){ref-type="supplementary-material"}) with weights the number of incident cases. Patients aged 15‐74 years](CAM4-8-4497-g001){#cam42276-fig-0001}

Table [3](#cam42276-tbl-0003){ref-type="table"} shows the observed number of patients alive at 10 years since diagnosis, the observed 5‐year CRS for patients alive 10 years after diagnosis, and the estimated number of years necessary for model‐based 5‐year CRS to exceed 90% or \>95%. Men and women who already survived 10 years showed an observed 5‐year CRS \>95% in all age groups when the diagnoses were colon cancer, skin melanoma, testicular and thyroid cancers (94% in 65‐74 years men). Patients with these cancer types indeed reached 5‐year CRS \>95% in less than 10 years (Table [3](#cam42276-tbl-0003){ref-type="table"}). Notably, TTC (with 95% threshold for 5‐year CRS) was reached in less than 1 year for thyroid cancer patients below the age of 55 years. Conversely, a small but non negligible excess risk of death was still present even after 15 years since diagnosis for women with breast cancer and men with prostate and bladder cancers. In both sexes, a clear long‐term excess risk of death emerged for most smoking‐related cancers (Appendices [S1](#cam42276-sup-0001){ref-type="supplementary-material"} and [S2](#cam42276-sup-0001){ref-type="supplementary-material"}), and for hemolymphopoietic neoplasms, except for Hodgkin lymphoma (Table [3](#cam42276-tbl-0003){ref-type="table"}).

###### 

Indicators of time to cure[a](#cam42276-note-0010){ref-type="fn"} by sex, cancer type[b](#cam42276-note-0011){ref-type="fn"}, and age in Italy

  Age (y)                   15‐44   45‐54   55‐64   65‐74                                                                                  
  ------------------------- ------- ------- ------- ------- -------- ------ ----- ------ -------- ----- ------ ------ ------- ----- ------ ------
  MEN                                                                                                                                      
  Oral cavity and pharynx   247     85%     13      18      485      82%    15    20     615      79%   16     \>20   343     76%   17     \>20
  Stomach                   163     97%     6       9       360      97%    6     8      658      97%   7      9      701     89%   11     16
  Colon                     349     99%     5       7       913      99%    5     7      2,204    97%   6      8      2,725   97%   6      9
  Rectum                    148     96%     7       9       476      98%    6     8      1,059    94%   8      11     1,177   94%   8      11
  Skin melanoma             820     99%     4       6       597      96%    5     9      643      98%   5      8      472     98%   6      8
  Connective tissue         158     96%     6       10      127      94%    7     12     134      93%   9      13     90      91%   10     14
  Prostate                  17      93%     6       14      575      92%    7     15     4,636    92%   8      16     8,719   91%   9      17
  Testicular                1,601   99%     \<1     \<1     251      100%   \<1   \<1    89       98%   1      1      23      94%   9      11
  Kidney                    398     96%     2       7       762      93%    6     17     1,481    91%   9      \>20   1,294   88%   14     \>20
  Bladder                   630     98%     \<1     1       1,605    95%    3     11     3,644    92%   9      16     4,347   90%   11     16
  Thyroid                   506     100%    \<1     \<1     276      96%    \<1   7      255      97%   6      9      145     94%   8      11
  Hodgkin lymphoma          792     97%     0       7       130      93%    7     15     101      80%   \>20   \>20   52      86%   12     16
  Non‐Hodgkin lymphoma      889     91%     8       \>20    678      89%    12    \>20   851      87%   15     \>20   742     85%   19     \>20
  NHL, diffuse large B      235     99%     4       6       151      95%    7     10     156      88%   12     \>20   141     88%   12     19
  NHL, follicular           160     92%     3       \>20    134      88%    20    \>20   137      83%   \>20   \>20   100     76%   \>20   \>20
  WOMEN                                                                                                                                    
  Oral cavity and pharynx   159     89%     12      \>20    179      85%    16    \>20   227      83%   19     \>20   263     80%   \>20   \>20
  Stomach                   120     99%     5       6       215      97%    7     9      430      97%   6      8      574     93%   9      13
  Colon                     344     100%    5       6       893      98%    5     7      1,993    98%   5      7      2,593   97%   6      8
  Rectum                    125     99%     5       7       363      97%    7     9      757      98%   6      8      880     96%   7      10
  Skin melanoma             1,281   97%     \<1     6       703      98%    2     6      697      96%   2      8      575     95%   6      10
  Connective tissue         141     97%     5       9       89       96%    7     10     125      95%   7      11     92      94%   8      12
  Breast                    5,785   92%     9       14      10,663   94%    5     12     11,539   92%   8      17     9,712   89%   12     \>20
  Cervix uteri              858     99%     3       6       589      100%   4     6      511      93%   8      13     349     90%   11     16
  Corpus uteri              355     96%     1       7       1,443    99%    1     4      2,395    95%   3      11     1,842   94%   6      11
  Ovary                     544     97%     5       9       558      94%    9     11     558      91%   10     13     362     93%   9      12
  Kidney                    214     100%    3       5       365      95%    4     11     684      92%   7      19     779     91%   10     \>20
  Bladder                   218     100%    \<1     2       330      99%    2     4      821      95%   5      10     1,126   94%   8      11
  Thyroid                   1,803   100%    \<1     \<1     1,111    99%    \<1   \<1    937      99%   \<1    3      560     98%   4      6
  Hodgkin lymphoma          750     97%     \<1     4       104      95%    \<1   11     94       85%   18     \>20   55      77%   20     \>20
  Non‐Hodgkin lymphoma      644     93%     4       17      590      91%    9     \>20   897      88%   15     \>20   889     85%   \>20   \>20
  NHL, diffuse large B      160     98%     4       7       110      92%    7     20     139      87%   14     \>20   166     83%   17     \>20
  NHL, follicular           128     95%     1       13      138      91%    9     \>20   198      87%   20     \>20   163     81%   \>20   \>20

At 10 years = Patients alive at 10 years since diagnosis; CRS, Conditional Relative Survival.

Patients alive at 10 years since diagnosis (At 10 years), observed 5‐year Conditional Relative Survival for patients alive 10 years after diagnosis (5/10 CRS), and years to reach 5‐year Conditional Relative Survival (5‐year CRS) \>90% or \>95%.

Cancer types with CF \>20% in men or women.

Model‐based 5‐year CRS centered in 1995.

John Wiley & Sons, Ltd

Figure [2](#cam42276-fig-0002){ref-type="fig"} shows CF and TTC for major cancer types with CF\>20%. Major patterns of cancer types emerged. The first included cancers with a CF \>80% and a TTC ≤5‐6 years (eg, testicular, thyroid, skin melanoma); the second, cancers with a CF of approximately 50% and a TTC \<10 years (colon, rectum); the third, cancers showing a CF of approximately 50% and TTC \>10 years (breast, prostate, and bladder). In addition, the most severe pattern included some cancer types with a CF \<20% (Figure [1](#cam42276-fig-0001){ref-type="fig"}) and uncertain TTC.

![Cure fraction (%) and time to cure^a^ by sex for selected cancer types^b^in Italy. ^a^Calculated in 2000 for the most frequent age group (Table [3](#cam42276-tbl-0003){ref-type="table"} and Appendix [S4](#cam42276-sup-0001){ref-type="supplementary-material"}), that is, 65‐74 years but Connective Tissue, Cervix uteri, Testis, Thyroid, and Hodgkin lymphoma (15‐44 years). ^b^Cancer types with CF \>20% in men or women](CAM4-8-4497-g002){#cam42276-fig-0002}

4. DISCUSSION {#cam42276-sec-0008}
=============

This study provided updated estimates of three relevant indicators of long‐term survival and cancer cure for Italian patients, which are still lacking in current cancer statistics.

The median LEFT increased 4‐5 months in both sexes between 1990 and 2000, with noteworthy variations across cancer types. Patients who died of prostate cancer had 2‐year longer median LEFT when diagnosed in 2000 (7.4 years), as compared to those diagnosed in 1990 (5.2). A similar increase emerged for breast cancer (from 8.1 to 9.4), while the median LEFT showed a small increase (\<2 months) for colon, rectal or lung cancers. In the same decade, an approximately 10% increase in CF was estimated for adult patients and, notably this increase was consistent across cancer types.

Our results, along with the findings from similar studies,[5](#cam42276-bib-0005){ref-type="ref"}, [6](#cam42276-bib-0006){ref-type="ref"}, [7](#cam42276-bib-0007){ref-type="ref"}, [8](#cam42276-bib-0008){ref-type="ref"}, [9](#cam42276-bib-0009){ref-type="ref"}, [10](#cam42276-bib-0010){ref-type="ref"} supported the characterization of four major patterns of cancer types which may correspond to specific follow‐up strategies. The less severe characterization included cancer types with 5‐year RS and CF \>80% (eg, testicular and thyroid cancers below age 55 years). For these good prognosis cancers less intense surveillance scheme may be warranted, because after one or two years since diagnosis no relevant excess mortality remained.[6](#cam42276-bib-0006){ref-type="ref"}, [9](#cam42276-bib-0009){ref-type="ref"}, [10](#cam42276-bib-0010){ref-type="ref"} Excess mortality became negligible in less than 10 years for patients below age 45 years with Hodgkin lymphoma, skin melanoma, and cervical cancer.[6](#cam42276-bib-0006){ref-type="ref"}, [23](#cam42276-bib-0023){ref-type="ref"}

A second group included cancer types with negligible excess risk of death within 10 years from diagnosis (eg, colorectal and younger patients with stomach cancer). For these cancers, however, only medium or low CFs have been reported (approximately 50% and 20%, respectively).[5](#cam42276-bib-0005){ref-type="ref"}, [6](#cam42276-bib-0006){ref-type="ref"}, [9](#cam42276-bib-0009){ref-type="ref"}, [10](#cam42276-bib-0010){ref-type="ref"}

In the third group, including women with breast cancer, despite dramatic improvements in survival over the past decades, a small (ie, 5‐year CRS \<10%) but persistent (for \>15 years) increased death risk was observed.[8](#cam42276-bib-0008){ref-type="ref"}, [10](#cam42276-bib-0010){ref-type="ref"}, [20](#cam42276-bib-0020){ref-type="ref"}, [24](#cam42276-bib-0024){ref-type="ref"}, [25](#cam42276-bib-0025){ref-type="ref"}, [26](#cam42276-bib-0026){ref-type="ref"} It should be noted, however, that less than half the women with breast cancer will die because of that cancer in the first 20 years following diagnosis (ie, 20‐year RS \>50%, Appendix [S2](#cam42276-sup-0001){ref-type="supplementary-material"}).[27](#cam42276-bib-0027){ref-type="ref"}, [28](#cam42276-bib-0028){ref-type="ref"} A very similar pattern emerged for patients with prostate and bladder cancers, for which a long follow‐up is needed.

The last group included cancer types showing 5‐year RS \<20% (eg, lung or pancreatic cancer),[5](#cam42276-bib-0005){ref-type="ref"}, [7](#cam42276-bib-0007){ref-type="ref"}, [9](#cam42276-bib-0009){ref-type="ref"}, [10](#cam42276-bib-0010){ref-type="ref"} whose patients in this group may hardly reach the same expected death rate of the general population, because of the severe prognoses of these specific neoplasms, and the competitive risks associated with lifestyle risk factors. In particular, a vast majority of respiratory tract cancer patients are smokers who carry a high risk of smoking‐related mortality.[29](#cam42276-bib-0029){ref-type="ref"} A similar excess of noncancer related mortality is expected for people infected with hepatitis C virus, a large proportion of liver cancer patients. These effects could result in reduced long‐term RS and in prolonged or indefinite TTC.

4.1. Strengths and limitations {#cam42276-sec-0009}
------------------------------

To the best of our knowledge, this is the first study reporting trends of LEFT and CF for a large number of cancer types. In addition, in this study a careful validation was conducted by comparing observed RS, 5‐years CRS, and the corresponding model‐based curves by follow‐up time to 25 years after diagnosis (Appendices [S1](#cam42276-sup-0001){ref-type="supplementary-material"} and [S2](#cam42276-sup-0001){ref-type="supplementary-material"}). The accuracy of the present estimates relied on the length of follow‐up and size of the study population. The follow‐up period appeared long enough to provide reliable estimates of median LEFT, CF, and TTC for several cancer types.[30](#cam42276-bib-0030){ref-type="ref"} Indeed, our survival estimates were based on a very large population‐based cohort of patients, which allowed estimates by some relevant histological subtype (ie, diffuse large‐B‐cell and follicular NHL, and SLL/CLL or acute myeloid leukemias).

A first limitation is related to the representativeness of our results at the national level, since the long‐established cancer registries contributing to this study cover only 10% of the Italian population. Variability across regions of present indicators cannot be excluded, although cancer registries were well distributed across all Italian areas.[11](#cam42276-bib-0011){ref-type="ref"} Moreover, the generalization of results to other countries, herein presented, is also uncertain albeit the Italian survival levels were similar to those of most central and southern European countries.[12](#cam42276-bib-0012){ref-type="ref"} Additional limitations are related to the use of cure models.[22](#cam42276-bib-0022){ref-type="ref"}, [31](#cam42276-bib-0031){ref-type="ref"} These models are influenced by the choice of the survival distribution of fatal tumors. Most importantly, the estimates are critical for cancers maintining a long‐term excess mortality risk because the follow‐up period available may not be sufficient to observe the deaths of all fatal cases, ie the plateau in the survival curve. This means that there might have been an identifiability issue of the CF and LEFT.[5](#cam42276-bib-0005){ref-type="ref"}, [22](#cam42276-bib-0022){ref-type="ref"} Moreover, it should be noted that the estimation of TTC is sensible to the choice of the CRS threshold and to the use of different definitions,[4](#cam42276-bib-0004){ref-type="ref"}, [6](#cam42276-bib-0006){ref-type="ref"}, [10](#cam42276-bib-0010){ref-type="ref"} in particular for prostate or breast cancer in women. To take into account these critical points, we validated all models in addition to provide observed 5‐year CRS estimates at a fixed time point (10 years after diagnosis) and of TTC at different thresholds (ie, 90% and 95%).[4](#cam42276-bib-0004){ref-type="ref"}, [6](#cam42276-bib-0006){ref-type="ref"} Finally, information on other important prognostic factors (ie, stage and treatment) is not routinely collected by Italian CRs, and population‐based studies with a long follow‐up can hardly allow fine stratifications to assess long‐term survival, or cure of small subgroups of patients exposed to fast‐changing therapies.

5. CONCLUSIONS {#cam42276-sec-0010}
==============

Our study confirmed, between 1990 and 2000 a general improvement of prognosis and cure of adult Italian cancer patients, measured here in terms of cure fraction and of life expectancy of fatal cases. The findings highlighted a 10% average increase of cure fraction for adult Italian cancer patients, and a 4‐5 months increase of median LEFT in a decade. Excess cancer mortality risk disappeared in \<10 years for testis, thyroid, colon cancers, and melanoma, while it remained for \>15 years for breast and prostate cancers.

Detailed (eg, by sex, age, year of diagnosis) estimates of different indicators of long‐term survival and cancer cure are useful to health professionals in enhancing the efficacy of long‐term follow‐up, a goal which can be reached through appropriate tools and procedures.[14](#cam42276-bib-0014){ref-type="ref"}, [32](#cam42276-bib-0032){ref-type="ref"}, [33](#cam42276-bib-0033){ref-type="ref"}

In conclusion, recognizing a cancer patient as cured, and quantifying his/her long‐term excess risk of death, represents a valuable opportunity to improve his/her quality of life[34](#cam42276-bib-0034){ref-type="ref"}, [35](#cam42276-bib-0035){ref-type="ref"} and social or professional perspectives, as well.[8](#cam42276-bib-0008){ref-type="ref"}
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